Duane Roth Endowed Award Lecture

2019 Symposium

2018 Symposium

2017 Symposium

2017 Symposium Photos

2016 Symposium

2015 Symposium

2015 Agenda and Bios

2015 Symposium Photos

2014 Symposium

2014 Agenda and Bios

2013 Featured Talks

2013 Symposium Photos

Previous Symposia

2019 Symposium

The 15th Moores Cancer Center Industry/Academia "Next Generation Precision Oncology" Symposium will be held on Thursday, February 21, 2019.

Confirmed Speakers:

Duane Roth Award Lecture
A Story of Drug Development: Taxol®, Tubulin and Tumors

Susan Band Horwitz, PhD

Distinguished Professor, Department of Molecular Pharmacology
Rose C. Falkenstein Chair in Cancer Research
Einstein College of Medicine
[+] Biography

Keynote Speaker
Delivering on the Promise of Precision Oncology

Gordon Mills, MD, PhD

Director, Precision Oncology, Knight Cancer Institute
Director, SMMART Trials, Knight Cancer Institute
Wayne and Julie Drinkward Endowed Chair, Precision Oncology, Knight Cancer Institute
Professor, Cell, Developmental and Cancer Biology
OHSU Knight Cancer Institute
[+] Biography

UC San Diego Welcome and Introduction
David Brenner, MD
Vice Chancellor, UC San Diego Health Sciences
[+] Biography

Moores Cancer Center Welcome
Joseph Califano, MD
Physician in Chief, Professor of Surgery, UC San Diego Moores Cancer Center
Director, Head and Neck Cancer Center
[+] Biography

Clinical Perspective: Targeting CTGF in Locally Advanced Pancreatic Cancer
Ewa Carrier, MD
Executive Director of Clinical Development, Fibrogen
[+] Biography

Organizer Welcome
Ida Deichaite, PhD
Director, Industry Relations, UC San Diego Moores Cancer Center
[+] Biography

Epigenetics in Glioblastoma
Laure Escoubet, PhD
Senior Director, Head of Epigenetic Drug Discovery, Celgene
[+] Biography

Ryan Fukushima, MBA
Chief Operating Officer, Tempus
[+] Biography

A bispecific antibody strategy to focus 4-1BB activation at sites of PD-L1 expression
Analeah Heidt, PhD
Vice President of Translational Research, Inhibrx
[+] Biography

Malignant Deamination Drives Cancer Stem Cell Generation
Catriona Jamieson, MD, PhD
Deputy Director, UC San Diego Moores Cancer Center
Professor of Medicine and Chief, Division of Regenerative Medicine
Koman Family Presidential Endowed Chair in Cancer Research
Deputy Director, Sanford Stem Cell Clinical Center
Director, CIRM Alpha Stem Cell Clinic
[+] Biography

There's No Place Like HOPE
Shumei Kato, MD
Assistant Clinical Professor, UC San Diego Moores Cancer Center
[+] Biography

Scott Lippman, MD
Director, UC San Diego Moores Cancer Center
[+] Biography

Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Yi Liu, PhD
Chief Scientific Officer and Senior Vice President, Wellspring Biosciences LLC
[+] Biography

The Molecular Characterization of Men with Metastatic Castration Resistant Prostate Cancer
Rana McKay, MD
Assistant Professor of Medicine, UC San Diego Moores Cancer Center
[+] Biography

There's No Place Like HOPE
Teresa McKeown
Patient Advocate
[+] Biography

Therapeutic Susceptibility of KRAS-Mutant Cancers to MRTX1257, a Covalent KRASG12C Inhibitor
Peter Olson, PhD
Director of Research, Mirati Therapeutics
[+] Biography

Use of Stem Cell Memory T Cells (Tscm) for the Creation of CAR-T Therapies with Superior Characteristics
Eric Ostertag, MD, PhD
CEO, Poseida Therapeutics
[+] Biography

Chair, Immuno-Oncology Session
Sandip Patel, MD
Associate Professor, Medical Oncology/Hematology, UC San Diego Moores Cancer Center
[+] Biography

Present and Future of Cabozantinib in GU Cancers
José Ricardo Pérez
Executive Medical Director, Medical Affairs, Exelixis
[+] Biography

Targeting stem cell signals in cancer heterogeneity and therapy resistance
Tannishtha Reya, PhD
Professor, Pharmacology and Medicine, UC San Diego
[+] Biography

The Control of Anti-Tumor Immunity and its Implications on Checkpoint Inhibitor Therapy
Shabnam Shalapour, PhD
Associate Professor of Pharmacology, UC San Diego
[+] Biography

Transcriptional Components and Signatures to Characterize the Cellular State of Individual Tumors
Pablo Tamayo, PhD
Director, UCSD Center for Cancer Target Discovery and Development
Professor, Division of Medical Genetics, UC San Diego Moores Cancer Center
[+] Biography

Drugging the Cancer Cell Cycle
Michael White, PhD
VP, Tumor Cell Biology, Chief Scientific Officer, Pfizer
[+] Biography

Controlling CAR-T Cell Therapy
Travis Young, PhD
VP, Biologics, California Institute for Biomedical Research (Calibr)
[+] Biography

2018 Symposium Featured Talks

Please enjoy the featured talks below from our recent symposium. Thank you!

Please note: These videos are for private viewing only. Any unintended use of the videos without consent is prohibited.

Keynote Presentation: Duane Roth Award Lecture
Engineering T-Cells: The Sky is the Limit

Carl June, MD
University of Pennsylvania School of Medicine

Keynote Presentation:
A New Model for Translational Research in the Nonprofit Sector

Peter Schultz, PhD
California Institute for Biomedical Research

Welcome Remarks

Ida Deichaite, PhD, Symposium Organizer, UC San Diego Moores Cancer Center
Pradeep Khosla, PhD, Chancellor, UC San Diego

Welcome Remarks

Thomas Kipps, MD, PhD
Symposium Chair, UC San Diego Moores Cancer Center

Patient Advocacy Presentation

Bryce Olson
Patient Advocate

In silico drug discovery of dual inhibitors of combinatorial synthetic lethality inhibitors in the era of prevision medical oncology; proof of concept

Donald Durden, MD, PhD
UC San Diego Moores Cancer Center

A Personalized Cancer Immunotherapy Paradigm: simple solutions to address complex options for patients

Priti Hedge, PhD

Mutational Signatures for Cancer Treatment and Cancer Prevention

Ludmil Alexandrov, PhD
UC San Diego Moores Cancer Center

A Patient Journey Through the Lens of a Digital Marketer

Brian McCloskey
Patient Advocate

Moores Cancer Center Overview

Ezra Cohen, MD
UC San Diego Moores Cancer Center

Inhibition of Difficult to Drug Tumor Cell and Immuno-Oncology targets with Next Generation Antisense Inhibitors

Robert MacLeod, PhD
Ionis Pharmaceuticals

Targeting PARP in Prostate Cancer: Promise and Pitfalls

Rana McKay, MD
UC San Diego Moores Cancer Center

Junior Faculty Presentation
Dual PI3K/BRS4 Inhibition as a Novel Therapeutic Strategy for Hepatocellular Carcinoma

Adam Burgoyne, MD, PhD
UC San Diego Moores Cancer Center

The New Generation of Antibody Drug Conjugates: Intersection of Target and Payload

Julia Coronella, PhD
Tanabe Research Labs

Gene Control Approach to Manipulate Cell State: Sensitizing Cancer Cells to Antibody-mediated attack

David Orlando, PhD
Syros Pharmaceuticals

Killing Cancer Stem Cells in Brain Cancer

Jeremy Rich, MD
UC San Diego Moores Cancer Center

For our out of town attendees: We recommend staying at the Estancia La Jolla Hotel and Spa for your lodging needs. The UCSD corporate rate is subject to availability and this rate is $195 when it is available. It is currently available for Wednesday, Feb. 20th, and rooms can be booked via this link. We encourage you to make your reservations as soon as possible due to availability.

2018 Symposium

The 14th Moores Cancer Center Industry/Academia Translational Oncology Symposium was held on Thursday, February 22, 2018. Learn more about it here.


Contemporary leaders of oncology are driven to redefine the notion of curative medicine by skillfully leveraging the power of collaboration to optimize everyone’s unique expertise and stretch research dollars in order to drive innovation. They are also changing clinical trial paradigms and emphasizing combination immunotherapy, new therapeutic modalities, and precision diagnosis. Already, as a result of these efforts, the oncology community can treat cancer patients and combat cancer at the molecular level.

The annual Industry/Academia "Next Generation Precision Oncology" Symposium at Moores Cancer Center, now celebrating its 15th year, was created to support multi-modality collaborations and foster new partnerships in order to speed new therapies to patients. Each year the Symposium’s esteemed presenters from around the world, including clinicians, researchers, and top decision makers from industry and academia, attest to just how necessary it was for them to surmount multiple obstacles, in and out of the lab, in order to achieve success and help patients. The forum provides a platform for oncology innovators to highlight their interdisciplinary approach, as opposed to discussion on a specific type of cancer. Case study presentations showcase successful efforts, the challenges that they encountered, and the lessons they have learned from the process.


To address the need for dialogue amongst all leaders of cancer research, the Symposium promotes interaction and discussion throughout the entire program. Invited speakers give presentations that range in length, and include a keynote presentation, numerous presenters from faculty and industry, young investigator presentation, interactive discussion panels, and poster sessions, highlighting rapidly emerging cancer science. Discussions continue throughout breaks and lunch, and culminate in a networking reception. Additionally, a dinner consisting of Symposium speakers and sponsors held prior to the event creates an opportunity for introductions to be made and work to be discussed in a relaxed, collegial setting. Through the Symposium’s emphasis on translational oncology and drug development, we shepherd researchers and physicians to foster fruitful, ongoing relationships and partnerships with local, regional, and national biotechnology and pharmaceutical companies, ultimately resulting in curative therapies that advance global cancer treatment paradigms.


The field of oncology is brimming with innovators and investigators ready to blaze new pathways for bringing the most effective novel therapies out of the laboratory to the patients. Clinicians, researchers, and top decision makers are critical in the process of translation to deliver curative cancer therapies. Our goal is to unite these individuals and provide a forum through which they can network and collaborate, while celebrating the community’s successful efforts.


  • Immunotherapy
  • Precision medicine
  • New therapeutic approaches in numerous cancers
  • Orphan drug oncology indications
  • Innovative clinical trial modalities
  • Funding innovation


San Diego provides an ideal environment for successful partnerships and collaborations: The intersection of academia, biomedical research, top-notch health care providers, and entrepreneurship allow innovation to abound. San Diego’s position as a global hub for biomedical innovation serves as a role model for translational oncology on a national level.

Symposium Organizers and Chairs

Symposium Organizers:

Scott Lippman, MD
UC San Diego Moores Cancer Center

Ida Deichaite, PhD
Director, Industry Relations
UC San Diego Moores Cancer Center

Symposium Co-Chairs:

Rafael Bejar, MD, PhD
Assistant Professor of Medicine
UC San Diego Moores Cancer Center

Tom Kipps, MD, PhD
Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research
Deputy Director of Research Operations
UC San Diego Moores Cancer Center

We Thank Our Supporters for the Upcoming Symposium: